Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor & HER2-Low Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HER2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HER2 (ERBB2) ECD-Fc Fusion Protein / Mutant Protein. High purity (>95%), Endotoxin <1EU/μg, HEK293 expressed, native glycosylation, sequence verified, theoretical MW confirmed. | View HER2 Products |
| Gene Delivery | HER2 Full-Length ORF Lentivirus (CMV promoter, puromycin selection). Ideal for stable cell lines and flow cytometry-based assays. | View HER2 Products |
| Benchmark Ab (Trastuzumab) | Anti-HER2 (Trastuzumab biosimilar sequence). Domain IV epitope, recombinant positive control for binding & ADCC assays. Endotoxin controlled. | View HER2 Products |
| Benchmark Ab (Pertuzumab) | Anti-HER2 (Pertuzumab biosimilar sequence). Domain II epitope, positive control for dimerization inhibition assay validation. | View HER2 Products |
| Validator | HER2 siRNA Set (3 target-specific + 1 scrambled). For knockdown verification and specificity controls. | View HER2 Products |
| Related Target A | HER3 (ERBB3). Primary heterodimerization partner of HER2; crucial for resistance bypass and bispecific targeting. Essential for combination therapy logic. | View HER3 Products |
| Related Target B | EGFR (HER1/ERBB1). Pan-HER family signaling partner; essential for selectivity counter-screening and bypass resistance studies. | View EGFR Products |
Critical Assay Solutions & Technical Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ADC Internalization & Glycosylation Dependency | HEK293 expressed (native glycosylation) ECD-Fc fusions to mimic physiological folding and receptor uptake. High purity (>95%) minimizes aggregate interference; Endotoxin <1EU/μg. |
| Cross-species Preclinical Translation (Cyno/Mouse) | Human, Cynomolgus, and Mouse HER2 ortholog proteins available with >95% purity, sequence verified for epitope conservation analysis. |
| Heterodimer Inhibition (Pertuzumab Mechanism) | Domain II-specific antigen presentation with theoretical MW confirmed by mass spec. |
| Epitope Binning & Lack of Reliable Controls | Clinical Benchmark Antibodies (Trastuzumab, Pertuzumab biosimilars) included with exact sequence fidelity for competition assays. |
| Cardiotoxicity Safety Screening | High-purity antigens for off-target binding assays; low endotoxin reduces assay noise. |
| Resistance Bypass Analysis | EGFR and HER3 proteins available for heterodimerization screening and resistance mechanism studies. |
| Specificity in Functional Cell Assays | Valid sequence Lentivirus particles and siRNA included for rigorous specificity checks (knockdown verification). |
Live HER2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HER2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies. As first-generation therapies (trastuzumab, pertuzumab, T-DM1) establish baseline survival benefits in HER2-positive breast and gastric cancers, the next wave of R&D is heavily targeting the "HER2-Low" and "HER2-Ultra-Low" pan-tumor populations (led by Enhertu). Overcoming acquired resistance — such as kinase domain mutations, HER3 upregulation, PI3K/AKT pathway activation, and HER2 truncation (p95-HER2) — and penetrating brain metastases with novel TKIs or next-generation ADC linker-payload formats represent the critical frontiers in the next decade of HER2 drug development. Combination strategies with immune checkpoint inhibitors, CDK4/6 inhibitors, and bispecific T-cell engagers are also gaining momentum.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Daiichi Sankyo/AstraZeneca (Enhertu), Roche (Kadcyla) | HER2-low breast cancer, NSCLC, gastric cancer | Internalization & lysosomal trafficking assay (need high-purity HEK293 ECD-Fc with native glycosylation) |
| Bispecific | Zymeworks/Jazz, Roche, Merus | Gastric cancer, refractory solid tumors | Heterodimer validation (need high-purity HER2/HER3 proteins; cross-reactive Abs) |
| TKI / Small Molecule | Seagen/Puma (tucatinib), Neratinib | Brain metastases, early-stage breast cancer | Selectivity assay (need mutant vs. WT kinase proteins; ERBB family panel) |
| Monoclonal Ab | Roche (Herceptin, Perjeta), MacroGenics (Margetuximab) | HER2+ early/metastatic breast cancer | Epitope binning, ADCC reporter assays, dimerization inhibition (need sequence-verified benchmark Abs) |
| CAR-T | Various clinical-stage biotechs | HER2+ solid tumors | Cell surface density calibration using Lentivirus standards |
Key Mutations and Functional Domains
HER2/ERBB2 (UniProt P04626) is a receptor tyrosine kinase with a protein kinase domain (residues 720–987). Clinically relevant mutations include:
- rs4252633 (VAR_016317): A missense variant in the kinase domain.
- rs1801201 (allele B3; VAR_004077): Located in the extracellular domain.
- rs1136201 (allele B2/B3; VAR_004078): Another common polymorphism.
These variants may influence drug sensitivity, resistance, or risk associations. TarMart provides recombinant mutant proteins for selective assay development.
Related Targets for Combination Strategies
- HER3 (ERBB3): Kinase-impaired; relies on HER2 for phosphorylation. HER3 upregulation is a major resistance mechanism to Enhertu. Recommended for bispecific (HER2×HER3) or combination therapy.
- EGFR (HER1): Heterodimer with HER2; counter-screen for selectivity to avoid EGFR-mediated toxicity (e.g., rash).
- TROP2: Competitive target in breast cancer sequencing; relevant for next-generation pan-tumor ADCs.